BBIOBridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) sells gene therapy and RNA-based treatments for rare genetic diseases, with a focus on muscular dystrophy and cardiomyopathies. Its next catalyst is Sep 23, 2026 — Q3 2026 Earnings Release, which will test the commercial momentum of its flagship drug, Attruby, and the progress of its NDA for BBP-418.
- Revenue surged 126.3% YoY to $669.46M, driven by Attruby’s rapid adoption.
- Free cash flow remains negative at -$1.14B TTM, with a debt-to-equity ratio of -0.96x.
- Shareholders’ equity is -$2.09B, reflecting the high capital intensity of biotech R&D.
The Read
9% after missing earnings expectations and facing insider selling, then rose 11%.
The schedule
- Wed23Sep
Q3 2026 results.
- Tue9Feb
Q4 2026 results.
- Wed12May
BridgeBio to Participate in May and June Investor Conferences
- Mon9Aug
Q2 2027 results.
- Tue10Aug
BridgeBio Pharma, Inc. (BBIO) - Yahoo Finance
- Thu9Sep
BridgeBio to Participate in September Investor Conferences
Past
- Mon10Aug
Actual outcome: Bear · $79.86 at outcome
Despite beating revenue expectations with Attruby sales more than tripling year-over-year and reaffirming its $1 billion global sales guidance, BridgeBio's stock declined following the print. The downward pressure was primarily driven by a wider-than-expected Q2 loss and the announcement of a 5 million share secondary public offering by existing stockholder KKR, which weighed on near-term sentiment.
Q2 2026 earnings print focusing on early commercial launch metrics for Attruby (acoramidis) and ongoing cash burn rates.
- Sun1Mar
Actual outcome: Bull · $73.15 at outcome
BridgeBio shares rallied 11.7% following a favorable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis, which had been a major point of investor focus. The positive momentum was further supported by management highlighting strong clinical progress, commercial momentum, and the announcement of additional data presentations from the Phase 3 FORTIFY trial.
- Tue24Feb
Actual outcome: Bear · $67.61 at outcome
BridgeBio reported a Q4 loss of $1.00 per share, missing the consensus estimate of $0.75, which overshadowed a revenue beat and prior positive clinical data for infigratinib. The stock's decline below the bear floor was further exacerbated by significant insider selling from the CEO and CFO just prior to the earnings release, signaling a lack of near-term confidence in the Acoramidis commercial ramp-up.
